Nanjing Pharmaceutical Group Company Limited (SHA:600713)
China flag China · Delayed Price · Currency is CNY
5.24
+0.06 (1.16%)
Sep 14, 2026, 3:00 PM CST

SHA:600713 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
54,66554,81053,56853,47350,07444,964
Other Revenue
153.12153.12128.05116.29147.48159.08
54,81854,96353,69653,59050,22245,123
Revenue Growth
0.71%2.36%0.20%6.71%11.30%13.33%
Cost of Revenue
51,42951,59750,34150,28346,96942,190
Gross Profit
3,3893,3663,3553,3073,2522,934
Selling, General & Admin
1,7441,7131,6661,6911,6451,509
Research & Development
44.8646.7930.6436.1927.4320.96
Other Operating Expenses
105.22116.3494.3196.35116.5591.37
Operating Expenses
2,0362,0181,8181,8071,8641,633
Operating Income
1,3531,3491,5371,5001,3891,301
Interest Expense
-303.89-309.01-325.82-522.23-332.9-439
Interest & Investment Income
27.0225.4317.6218.7211.4113.17
Other Non Operating Income (Expenses)
-228.13-217.58-218.47-19.42-136.95-17.44
EBT Excluding Unusual Items
848.49847.441,011977.09930.24857.44
Impairment of Goodwill
-8.92-8.92----
Gain (Loss) on Sale of Investments
1.790.28---48.64-87.74
Gain (Loss) on Sale of Assets
287.63293.313.771.7523.7960.54
Asset Writedown
-0.39-----
Other Unusual Items
25.5125.51-10.94-0.770.638.63
Pretax Income
1,1541,1581,003978.07906.01838.87
Income Tax Expense
322.7324.96260.28265.26190.09228.31
Earnings From Continuing Operations
831.42832.67743.12712.81715.92610.55
Minority Interest in Earnings
-203.39-207.83-172.49-134.98-120.25-105.37
Net Income
628.03624.83570.63577.83595.67505.18
Net Income to Common
628.03624.83570.63577.83595.67505.18
Net Income Growth
14.07%9.50%-1.25%-3.00%17.91%34.21%
Shares Outstanding (Basic)
1,2891,3021,3031,2981,2541,042
Shares Outstanding (Diluted)
1,4751,4671,3031,2981,2541,042
Shares Change
6.96%12.58%0.33%3.54%20.39%-0.10%
EPS (Basic)
0.490.480.440.450.470.48
EPS (Diluted)
0.430.430.440.450.470.48
EPS Growth
6.65%-2.74%-1.57%-6.32%-2.06%34.35%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-1,256-159.571,5911,748-837.59388.79
Free Cash Flow Per Share
-0.85-0.111.221.35-0.670.37
Dividend Per Share
0.1700.1700.1700.1600.1400.120
Dividend Growth
0%0%6.25%14.29%16.67%9.09%
Gross Margin
6.18%6.12%6.25%6.17%6.48%6.50%
Operating Margin
2.47%2.45%2.86%2.80%2.77%2.88%
Profit Margin
1.15%1.14%1.06%1.08%1.19%1.12%
Free Cash Flow Margin
-2.29%-0.29%2.96%3.26%-1.67%0.86%
EBITDA
1,4981,4951,6911,6541,5431,448
EBITDA Margin
2.73%2.72%3.15%3.09%3.07%3.21%
D&A For EBITDA
144.61146.15154.02153.76153.84147.27
EBIT
1,3531,3491,5371,5001,3891,301
EBIT Margin
2.47%2.45%2.86%2.80%2.77%2.88%
Effective Tax Rate
27.96%28.07%25.94%27.12%20.98%27.22%
Revenue as Reported
54,81854,96353,69653,59050,22245,123